Actualités Poniard Pharmaceuticals, Inc. (MM) - PARD | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

- Prospectus filed pursuant to Rule 424(b)(3) (424B3)

Table of Contents Prospectus filed pursuant to Rule 424(b)(3) Registration No. 333-175778 PONIARD...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

- Quarterly Report (10-Q)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Filed by Poniard Pharmaceuticals, Inc. pursuant to Rule 425 under the Securities Act of 1933, as amended...

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A...

- Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Poniard Pharmaceuticals, Inc. (MM) (PARD)

Outils de qualité professionnelle, pour des investisseurs individuels.

PARD Actualités

- Current report filing (8-K)

- Current report filing (8-K)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Prospectus filed pursuant to Rule 424(b)(3) (424B3)

- Current report filing (8-K)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Quarterly Report (10-Q)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

- Current report filing (8-K)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Poniard Pharmaceuticals, Inc. (MM) (PARD) Actualités

Poniard Pharmaceuticals, Inc. (MM) (PARD)

Outils de qualité professionnelle, pour des investisseurs individuels.

PARD Actualités

- Current report filing (8-K)

- Current report filing (8-K)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Prospectus filed pursuant to Rule 424(b)(3) (424B3)

- Current report filing (8-K)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Quarterly Report (10-Q)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

- Additional Proxy Soliciting Materials (definitive) (DEFA14A)

- Current report filing (8-K)

- Filing of certain prospectuses and communications in connection with business combination transactions (425)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application